Nurix Therapeutics Inc to Discuss Data Presented at ASH Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Liu - Lucid Capital Markets LLC - Analyst : Congrats on the data and thanks for the question. Chris from Lucid Capital Markets. Maybe one for Dr. Allen Karr. With this new data that we've gotten, do you have any new thoughts on how bexobrutideg compares to other BTK degraders in development? Allen Karr - University of Miami So main thing that we have -- what was presented here at ASH with the B1, the greater -- I think that's the best 1 that we have to compare. We really don't have a lot of information on the AbbVie degrader, what it has done, where it is. So we see between both, and that's what was just demonstrated on Saturday, is that it seems that bexobrutideg has a little bit of a more not only better, more solid follow-up data, so more solid responses and follow-up, but better tolerability. We see less of these issues of concerns with cytopenias and infectors complications. So the numbers are relatively similar -- numbers a little bit better with Bexdeg. So that's really the best that we have today. It's really the fact that, yeah, the class is extremely important. The best thing that we have is what was presented this weekend. And from the comparison that we have, it seems that there is really advantage that probably reflects what we're just seeing the fact that it's more selective and even more effective and with that, a little bit of a better response rate and less toxicity.